The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Acceleron Pharma Inc COM 00434H108 4,768 156,880 SH   SOLE   156,880 0 0
Adverum Biotechnologies Inc COM 00773U108 700 280,000 SH   SOLE   280,000 0 0
Akari Therapeutics Plc COM 00972G108 1,965 426,297 SH   SOLE   426,297 0 0
ARCA biopharma Inc COM 00211Y100 2,589 1,078,932 SH   SOLE   1,078,932 0 0
Argenx COM 04016X101 13,615 647,015 SH   SOLE   647,015 0 0
Ascendis Pharma A/S COM 04351P101 27,385 986,492 SH   SOLE   986,492 0 0
AveXis Inc COM 05366U100 76,959 1,035,657 SH   SOLE   1,035,657 0 0
Axovant Sciences Ltd COM G0750W104 6,997 301,718 SH   SOLE   301,718 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 13,762 2,475,167 SH   SOLE   2,475,167 0 0
Biohaven Pharmaceuticals COM G11196105 37,930 1,664,300 SH   SOLE   1,664,300 0 0
CytomX Therapeutics Inc COM 23284F105 4,478 288,915 SH   SOLE   288,915 0 0
DBV Technologies COM F2927N109 18,935 373,617 SH   SOLE   373,617 0 0
Edge Therapeutics Inc COM 279870109 19,839 1,933,582 SH   SOLE   1,933,582 0 0
Kalvista Pharmaceuticals COM 483497103 1,631 221,651 SH   SOLE   221,651 0 0
Lipocine Inc COM 53630X104 1,555 386,928 SH   SOLE   386,928 0 0
Obseva SA COM H5861P103 1,283 150,000 SH   SOLE   150,000 0 0
Ocera Therapeutics COM 67552A108 1,413 1,217,872 SH   SOLE   1,217,872 0 0
Ra Pharmaceuticals COM 74933V108 14,426 769,771 SH   SOLE   769,771 0 0
Sierra Oncology Inc COM 82640U107 153 130,798 SH   SOLE   130,798 0 0